GABELLI & Co INVESTMENT ADVISERS INC. Lowers Holdings in Surgery Partners, Inc. $SGRY

GABELLI & Co INVESTMENT ADVISERS INC. decreased its position in Surgery Partners, Inc. (NASDAQ:SGRY) by 67.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,200 shares of the company’s stock after selling 98,050 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC.’s holdings in Surgery Partners were worth $1,043,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SGRY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Surgery Partners by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,693 shares of the company’s stock worth $1,085,000 after acquiring an additional 2,015 shares during the period. Millennium Management LLC increased its holdings in Surgery Partners by 1,253.7% during the first quarter. Millennium Management LLC now owns 202,274 shares of the company’s stock valued at $4,804,000 after buying an additional 219,806 shares during the last quarter. Empowered Funds LLC raised its position in Surgery Partners by 11.0% in the first quarter. Empowered Funds LLC now owns 12,853 shares of the company’s stock worth $305,000 after acquiring an additional 1,278 shares during the period. AlphaQuest LLC boosted its stake in shares of Surgery Partners by 94.4% during the 2nd quarter. AlphaQuest LLC now owns 2,057 shares of the company’s stock worth $46,000 after acquiring an additional 999 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Surgery Partners by 7.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 32,763 shares of the company’s stock valued at $728,000 after buying an additional 2,284 shares in the last quarter.

Surgery Partners News Summary

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Several analysts maintained buy/outperform ratings despite lowering targets, signaling continued conviction in recovery potential. Analyst Expectations For Surgery Partners’s Future
• Positive Sentiment: TD Cowen cut its price target to $20 but kept a “buy” rating, implying substantial upside from current levels if company execution improves. TD Cowen lowers PT to $20, keeps Buy
• Positive Sentiment: UBS trimmed its target to $21 while retaining a “buy” stance, another signal that analysts still see medium‑term upside despite near‑term weakness. UBS lowers PT to $21, keeps Buy
• Neutral Sentiment: Some commentary frames the current slump as a potential buying opportunity for long‑term investors, but emphasizes execution and margin recovery are key. Has Surgery Partners Slump Opened A New Opportunity For Investors?
• Negative Sentiment: Barclays cut its price target sharply to $14, signaling more conservative near‑term expectations and adding downward pressure on the stock. Barclays Lowers Surgery Partners Price Target to $14
• Negative Sentiment: Q4 results: revenue modestly beat, but EPS missed expectations and management flagged margin pressure — the core reason for the selloff and heightened execution risk. SGRY Q4 2025 Earnings Call Highlights
• Negative Sentiment: Shares hit a new 52‑week low after the earnings miss and analyst downgrades, reflecting elevated near‑term downside and investor concern about margin recovery. Surgery Partners Sets New 52-Week Low on Disappointing Earnings

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SGRY. Benchmark reissued a “buy” rating on shares of Surgery Partners in a report on Tuesday. UBS Group dropped their price objective on shares of Surgery Partners from $29.00 to $21.00 and set a “buy” rating for the company in a report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. JPMorgan Chase & Co. reduced their target price on Surgery Partners from $27.00 to $20.00 and set a “neutral” rating on the stock in a report on Monday, November 24th. Finally, Barclays dropped their price target on Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.45.

Surgery Partners Stock Performance

Shares of NASDAQ:SGRY opened at $13.36 on Friday. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -21.55 and a beta of 1.95. The company has a quick ratio of 1.72, a current ratio of 1.87 and a debt-to-equity ratio of 1.15. The firm has a 50 day moving average of $15.20 and a 200 day moving average of $18.15. Surgery Partners, Inc. has a 52 week low of $12.25 and a 52 week high of $24.64.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The firm had revenue of $885.00 million during the quarter, compared to the consensus estimate of $866.54 million. During the same quarter in the prior year, the business posted $0.44 earnings per share. The firm’s quarterly revenue was up 2.4% on a year-over-year basis. On average, sell-side analysts predict that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Surgery Partners announced that its board has approved a share buyback program on Thursday, February 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to buy up to 9.7% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.